Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
These 10 medications are likely targets for Medicare price negotiations this fall
01:22pm, Thursday, 10'th Aug 2023
It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.
Bristol Myers Squibb stock extends bounce after announced $4 billion accelerated buyback agreements
07:08am, Thursday, 10'th Aug 2023
Shares of Bristol Myers Squibb Co. BMY, +0.76% got a 0.9% bump up in premarket trading Thursday, after the biopharmaceutical company announced $4 billion in accelerated share repurchase agreements. Th
Should Dividend Investors Buy Bristol Myers Stock?
08:45am, Sunday, 06'th Aug 2023
Deteriorating Revlimid sales weighed on second-quarter results. Still, the drugmaker offers a generous and sustainable dividend.
Here's Why Investors Should Buy These 2 Medical Stocks After Earnings
02:59am, Thursday, 03'rd Aug 2023
Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock.
Time To Go Defensive With These ETFs
04:05am, Wednesday, 02'nd Aug 2023
High-beta stocks have outperformed defensive stocks in the stock market recently, raising questions about the effectiveness of low-volatility and dividend growth investing. ROBECO's research shows tha
Looking for a Bargain? 7 Blue-Chip Stocks to Buy That Are Down 5% in 2023
07:10am, Tuesday, 01'st Aug 2023
The allure of discounted blue-chip stocks shines brighter than ever amid the complex mosaic of the stock market. With the stock market witnessing a rise driven by a handful of names, the flip side rev
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
07:01am, Tuesday, 01'st Aug 2023
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Bristol-Myers Squibb's Bright Future Unfolds Beyond Q2 2023 Turmoil
08:03am, Saturday, 29'th Jul 2023
Bristol-Myers Squibb's revenue for the second quarter of 2023 was $11.23 billion, down 0.97% from the previous quarter and 5.6% from the second quarter of 2022. Sales of Opdualag, an FDA-approved drug
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered
03:28pm, Thursday, 27'th Jul 2023
Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.
Bristol-Myers Squibb Company (BMY) Q2 2023 Earnings Call Transcript
12:37pm, Thursday, 27'th Jul 2023
Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2023 Earnings Call Transcript July 27, 2023 8:00 AM ET Company Participants Timothy Power - VP & Head, IR Giovanni Caforio - Chairman & CEO David Elkins - E
Compared to Estimates, Bristol Myers (BMY) Q2 Earnings: A Look at Key Metrics
11:42am, Thursday, 27'th Jul 2023
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti
2 Dirt Cheap Dividend Stocks to Buy Right Now
09:37am, Thursday, 27'th Jul 2023
Bristol Myers' innovative wheel should keep revenue moving in the right direction. Pfizer's success in the coronavirus market is helping fund other potential products.
Bristol Myers Slashes Forecast on Tumbling Revlimid Sales
08:13am, Thursday, 27'th Jul 2023
Cancer-fighting drugs Revlimid and Pomalyst drive a sales shortfall in the second quarter.
Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid sales
07:17am, Thursday, 27'th Jul 2023
Shares of Bristol Myers Squibb Co. BMY, -0.56% shed 2.2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its full-year outlook, amid a more rapid
Bristol Myers sales fall, cuts 2023 forecast as drugs face competition
07:02am, Thursday, 27'th Jul 2023
Drugmaker Bristol Myers Squibb said on Thursday its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood thinn
